450 related articles for article (PubMed ID: 28832957)
21. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Kim ES; Dhillon S
Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib for the treatment of mantle cell lymphoma.
Herrera AF; Jacobsen ED
Clin Cancer Res; 2014 Nov; 20(21):5365-71. PubMed ID: 25361916
[TBL] [Abstract][Full Text] [Related]
24. Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
Rai S; Tanizawa Y; Cai Z; Huang YJ; Taipale K; Tajimi M
Adv Ther; 2022 Oct; 39(10):4792-4807. PubMed ID: 35984628
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
26. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L
Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Zhang Y; Liu P; Cai J; Jing H; Zou L; Huang H; Wu Y; Li W; Zhong L; Jin X; Ye X; Feng R; Zhang H; Zhang L; Lin L; Sun X; Tian Y; Xia Z; Li Z; Huang H; Xia Y; Cai Q
Cancer Med; 2022 Nov; 11(22):4134-4145. PubMed ID: 35438258
[TBL] [Abstract][Full Text] [Related]
28. A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma.
Lee YP; Jung YJ; Cho J; Ko YH; Kim WS; Kim SJ; Yoon SE
Blood Res; 2023 Dec; 58(4):208-220. PubMed ID: 38151961
[TBL] [Abstract][Full Text] [Related]
29. Novel therapies for relapsed/refractory mantle cell lymphoma.
Arora PC; Portell CA
Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
January
Prescrire Int; 2016 Apr; 25(170):89-92. PubMed ID: 27183765
[TBL] [Abstract][Full Text] [Related]
32. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
Epperla N; Zhao Q; Chowdhury SM; Shea L; Moyo TK; Reddy N; Sheets J; Weiner DM; Geethakumari PR; Kandarpa M; Bruno XJ; Thomas C; Churnetski MC; Hsu A; Zurbriggen L; Tan C; Lindsey K; Maakaron J; Caimi PF; Torka P; Bello C; Ayyappan S; Karmali R; Kim SH; Kress A; Kothari S; Sawalha Y; Christian B; David KA; Greenwell IB; Janakiram M; Kenkre VP; Olszewski AJ; Cohen JB; Palmisiano N; Umyarova E; Wilcox RA; Awan FT; Alderuccio JP; Barta SK; Grover NS; Ghosh N; Bartlett NL; Herrera AF; Shouse G
J Hematol Oncol; 2022 Jul; 15(1):96. PubMed ID: 35842643
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C; Cheah CY; Eyre TA; Tucker D; Klener P; Giné E; Crucitti L; Muzi C; Iadecola S; Infante G; Bernard S; Auer RL; Pagani C; Duglosz-Danecka M; Mocikova H; van Meerten T; Cencini E; Marin-Niebla A; Williams ME; Angelillo P; Nicoli P; Arcari A; Morello L; Mannina D; Vitagliano O; Sartori R; Chiappella A; Sciarra R; Stefani PM; Dreyling M; Seymour JF; Visco C
Blood; 2022 Oct; 140(17):1907-1916. PubMed ID: 35789260
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
[TBL] [Abstract][Full Text] [Related]
35. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
Ghosh N; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Huang Q
Clin Ther; 2021 Aug; 43(8):1285-1299. PubMed ID: 34332789
[TBL] [Abstract][Full Text] [Related]
36. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Jain P; Zhao S; Lee HJ; Hill HA; Ok CY; Kanagal-Shamanna R; Hagemeister FB; Fowler N; Fayad L; Yao Y; Liu Y; Moghrabi OB; Navsaria L; Feng L; Nogueras Gonzalez GM; Xu G; Thirumurthi S; Santos D; Iliescu C; Tang G; Medeiros LJ; Vega F; Avellaneda M; Badillo M; Flowers CR; Wang L; Wang ML
J Clin Oncol; 2022 Jan; 40(2):202-212. PubMed ID: 34797699
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.
Williams AM; Baran AM; Casulo C; Reagan P; Friedberg JW; Helber M; Moore J; Baloga E; Zent CS; Barr PM
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):41-47. PubMed ID: 30409718
[TBL] [Abstract][Full Text] [Related]
39. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
40. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
Huang X; Qiu L; Jin J; Zhou D; Chen X; Hou M; Hu J; Hu Y; Ke X; Li J; Liang Y; Liu T; Lv Y; Ren H; Sun A; Wang J; Zhao C; Salman M; Sun S; Howes A; Wang J; Wu P; Li J
Cancer Med; 2018 Apr; 7(4):1043-1055. PubMed ID: 29533000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]